A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency

Pembrolizumab is an anti-programmed cell death protein-1 antibody that is mainly used for the treatment of non-small cell lung cancer (NSCLC). Immune-related adverse events can be caused by immune checkpoint inhibitors; however, few case reports evaluate the prognosis of patients with NSCLC with lat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonehara, Kei, Tateishi, Kazunari, Hirabayashi, Taro, Araki, Taisuke, Ikuyama, Yuichi, Machida, Ryosuke, Hanaoka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879310/
https://www.ncbi.nlm.nih.gov/pubmed/33613234
http://dx.doi.org/10.1159/000508068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879310/
https://www.ncbi.nlm.nih.gov/pubmed/33613234
http://dx.doi.org/10.1159/000508068

Ejemplares similares